Highest-materiality recent filing
Tandem Diabetes terminates CCO Mark Novara without cause; last day May 18
Mark Novara, EVP & Chief Commercial Officer, notified of termination without cause on May 11, 2026.
Tandem Diabetes closes $300M zero-coupon convertible notes due 2032; net proceeds ~$290.7M
Issued $300M aggregate principal of 0.00% Convertible Senior Notes due 2032 (including $35M greenshoe exercised).
Tandem Diabetes receives FDA 510(k) clearance for SteadiSet infusion set for 7-day use
FDA cleared SteadiSet infusion set for up to seven days of use; features integrated inserter with hidden needle.
Tandem settles patent disputes with Roche, agrees to pay $36M over five years
Settlement resolves pending patent actions in France and Germany regarding t:slim X2 pump and two EP patents.
CE mark granted for Tandem Mobi insulin delivery system with Control-IQ+ technology.
FDA cleared SteadiSet infusion set for up to 3 days of use; submission by subsidiary CapBio.
Tandem and Dexcom amend agreements to integrate Sigi pump with G7 CGM for five years
On May 22, 2024, Tandem and Dexcom entered into two amended and restated agreements.
FDA clears Tandem Mobi insulin pump for pediatric use ages 2+
FDA cleared Tandem Mobi insulin pump for expanded pediatric indication in individuals two years and older.
Issued $316.25M aggregate principal amount of 1.50% Convertible Senior Notes due 2029, including full exercise of initial purchasers' option for additional $41.25M.
Tandem Diabetes COO David Berger to step down Dec 31, 2023
David B. Berger, EVP and COO, will leave his role effective December 31, 2023.
Tandem Diabetes receives FDA clearance for t:slim X2 pump and Control-IQ for children 2+
FDA cleared 510(k) applications for t:slim X2 insulin pump and Control-IQ technology enhancements on Nov 3, 2023.
Tandem Diabetes Q1 revenue $186M, up 14% YoY; net loss $(49.1M)
Revenue $186.0M (+14% YoY); GAAP net loss $(49.1M) or $(0.75) per share.
Kim Blickenstaff steps down as Chair but remains a board member; served as Chair since March 2020.
Tandem Diabetes completes acquisition of AMF Medical for CHF 70.4M upfront plus earnouts
Total upfront consideration: CHF 8.0M strategic investment (Q3 2022) plus CHF 62.4M cash at closing.
Tandem Diabetes Care to acquire AMF Medical (Sigi Patch Pump) for up to CHF 200M
Cash payment of CHF 62.4M at closing plus CHF 8M prior strategic investment; earnouts up to CHF 129.6M.
Tandem Diabetes Q4 sales $210M (+25% YoY); FY2021 sales $703M (+41%); 2022 guide $845-860M
Full-year 2021 sales $702.8M (+41% YoY); net income $15.6M vs loss $34.4M in 2020.
FDA clears Tandem Diabetes t:slim X2 insulin pump to deliver bolus via smartphone app
FDA cleared t:slim X2 insulin pump to program and cancel bolus insulin doses using t:connect mobile app on iOS and Android.
Tandem Diabetes Q3 sales $179.6M (+45% YoY); raises FY2021 sales guidance to $685-695M
Q3 sales $179.6M (+45% YoY); net income $5.8M vs loss $9.4M; adjusted EBITDA $26.9M (15% of sales).
On May 11, 2026, Mark Novara, the Executive Vice President and Chief Commercial Officer of Tandem Diabetes Care, Inc. (the “Company”), was notified that his employment with the Company is being terminated without cause.
On June 19, 2024, the Board of Directors of Tandem Diabetes Care, Inc. (the “Company”) approved the appointment of Jean-Claude Kyrillos as Executive Vice President, Chief Operating Officer effective June 21, 2024.
on November 7, 2023, the Company and David B. Berger, the Company’s Executive Vice President and Chief Operating Officer, determined that Mr. Berger will be stepping down from his current position effective December 31, 2023.
On November 7, 2023, Tandem Diabetes Care, Inc. (“Tandem” or the “Company”) and David B. Berger, the Company’s Executive Vice President and Chief Operating Officer, determined that he will be stepping down from his current position effective December 31, 2023.
On August 17, 2023, Brian B. Hansen, Executive Vice President and Chief Commercial Officer of Tandem Diabetes Care, Inc. (the Company), notified the Company of his decision to resign from his role as Executive Vice President and Chief Commercial Officer, effective December 31, 2023.
Rebecca Robertson will succeed Kim D. Blickenstaff as Chair of the Board of Directors (the “Board”), effective March 1, 2023.
Mr. Allen will transition from the role of Lead Independent Director to a member of the Board.
Mr. Blickenstaff will transition from the role of Chair of the Board to a member of the Board
elected Joao Malagueira, age 56, to serve as a Class I director on the Board
elected Myoung Cha, age 45, to serve as a Class III director on the Board
On March 11, 2022, Douglas A. Roeder, notified the Company of his decision not to stand for re-election at the Company’s 2022 Annual Meeting of Stockholders
On February 3, 2022, the Board of Directors appointed David B. Berger, age 52, to serve as the Company’s Executive Vice President, Chief Operating Officer and Assistant Secretary.
Max materiality 0.80 · Median 0.50 · Most common event earnings